Cover Image
Market Research Report
Product code 
1110930

Europe Cardiac Safety Services Market - Industry Trends and Forecast to 2029

Published: | Data Bridge Market Research Private Limited | 173 Pages | Delivery time: Inquiry

Price

Back to Top
Europe Cardiac Safety Services Market - Industry Trends and Forecast to 2029
Published: April 1, 2022
Data Bridge Market Research Private Limited
Content info: 173 Pages
Delivery time: Inquiry
  • Description
  • Table of Contents
  • List of Tables

Europe cardiac safety services market is projected to register a substantial CAGR of 14.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Europe cardiac safety services market are:

Technological advances in research and development, and drug discovery

Increase in prevalence of cardiovascular diseases

Market Players:

The key market players for Europe cardiac safety services market are listed below:

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

IQVIA

Medpace

Ncardia

Certara

Eurofins Scientific

SGS SA

Banook

Celerion

Biotrial

Richmond Pharmacology

PhysioStim

TABLE OF CONTENTS

1 INTRODUCTION 26

  • 1.1 OBJECTIVES OF THE STUDY 26
  • 1.2 MARKET DEFINITION 26
  • 1.3 OVERVIEW OF EUROPE CARDIAC SAFETY SERVICES MARKET 26
  • 1.4 LIMITATIONS 27
  • 1.5 MARKETS COVERED 28

2 MARKET SEGMENTATION 30

  • 2.1 MARKETS COVERED 30
  • 2.2 GEOGRAPHICAL SCOPE 31
  • 2.3 YEARS CONSIDERED FOR THE STUDY 32
  • 2.4 CURRENCY AND PRICING 32
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
  • 2.6 MULTIVARIATE MODELLING 36
  • 2.7 SERVICES LIFELINE CURVE 36
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
  • 2.9 DBMR MARKET POSITION GRID 38
  • 2.10 MARKET END USER GRID 40
  • 2.11 VENDOR SHARE ANALYSIS 41
  • 2.12 SECONDARY SOURCES 42
  • 2.13 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 46

  • 4.1 PORTERS FIVE FORCES 47
  • 4.2 PESTEL ANALYSIS 48

5 EPIDEMIOLOGY 49

  • 5.1 INCIDENCE OF ALL BY GENDER 49
  • 5.2 TREATMENT RATE 50
  • 5.3 MORTALITY RATE 50
  • 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51

6 INDUSTRY INSIGHT 52

  • 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
  • 6.2 PATENT ANALYSIS 53
  • 6.3 PATENT FLOW DIAGRAM 54
  • 6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
  • 6.5 PRICING STRATEGY 57

7 EUROPE CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58

8 MARKET OVERVIEW 61

  • 8.1 DRIVERS 63
    • 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
    • 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
    • 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
    • 8.1.4 INCREASE IN R&D ACTIVITIES 64
  • 8.2 RESTRAINTS 65
    • 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
    • 8.2.2 STRICT REGULATORY 65
  • 8.3 OPPORTUNITIES: 66
    • 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
    • 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
  • 8.4 CHALLENGES 67
    • 8.4.1 TIME-CONSUMING PROCEDURE 67
    • 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68

9 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69

  • 9.1 OVERVIEW 70
  • 9.2 ECG/HOLTER MEASUREMENTS 74
  • 9.3 BLOOD PRESSURE MEASUREMENTS 74
  • 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
    • 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
      • 9.4.1.1 1 CONCENTRATIONS 76
      • 9.4.1.2 4 CONCENTRATIONS 76
    • 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
      • 9.4.2.1 3 CONCENTRATIONS 77
      • 9.4.2.2 5 CONCENTRATIONS 77
    • 9.4.3 IN VITRO HERG ASSAY 77
    • 9.4.4 OTHERS 77
  • 9.5 CARDIOVASCULAR IMAGING 77
  • 9.6 REAL TIME TELEMETRY MONITORING 78
  • 9.7 CENTRAL OVER-READ OF ECGS 79
  • 9.8 NON-INVASIVE CARDIAC IMAGING 79
  • 9.9 PHYSIOLOGIC STRESS TESTING 80
  • 9.10 THOROUGH QT STUDIES 81
  • 9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
  • 9.12 PLATELET AGGREGATION 82
  • 9.13 OTHERS 83

10 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE 84

  • 10.1 OVERVIEW 85
  • 10.2 PHASE I 88
  • 10.3 PHASE II 88
  • 10.4 PHASE III 89

11 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE 90

  • 11.1 OVERVIEW 91
  • 11.2 INTEGRATED SERVICES 94
  • 11.3 STANDALONE SERVICES 95

12 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER 96

  • 12.1 OVERVIEW 97
  • 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS 100
  • 12.4 ACADEMIC AND RESEARCH INSTITUTE 101

13 EUROPE CARDIAC SAFETY SERVICES MARKET, BY REGION 102

  • 13.1 EUROPE 103
    • 13.1.1 GERMANY 111
    • 13.1.2 FRANCE 114
    • 13.1.3 U.K. 117
    • 13.1.4 ITALY 120
    • 13.1.5 SPAIN 123
    • 13.1.6 TURKEY 126
    • 13.1.7 RUSSIA 129
    • 13.1.8 NETHERLANDS 132
    • 13.1.9 SWITZERLAND 135
    • 13.1.10 BELGIUM 138
    • 13.1.11 REST OF EUROPE 141

14 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 142

  • 14.1 COMPANY SHARE ANALYSIS: EUROPE 142

15 COMPANY PROFILE 143

  • 15.1 EUROFINS SCIENTIFIC 143
    • 15.1.1 COMPANY SNAPSHOT 143
    • 15.1.2 REVENUE ANALYSIS 144
    • 15.1.3 COMPANY SHARE ANALYSIS 144
    • 15.1.4 PRODUCT PORTFOLIO 144
    • 15.1.5 RECENT DEVELOPMENTS 145
      • 15.1.5.1 AGREEMENTS 145
      • 15.1.5.2 ACQUISITION 145
  • 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 146
    • 15.2.1 COMPANY SNAPSHOT 146
    • 15.2.2 REVENUE ANALYSIS 146
    • 15.2.3 COMPANY SHARE ANALYSIS 147
    • 15.2.4 PRODUCT PORTFOLIO 147
    • 15.2.5 RECENT DEVELOPMENT 147
      • 15.2.5.1 INVESTMENT 147
  • 15.3 KONINKLIJKE PHILIPS N.V. 148
    • 15.3.1 COMPANY SNAPSHOT 148
    • 15.3.2 REVENUE ANALYSIS 148
    • 15.3.3 COMPANY SHARE ANALYSIS 149
    • 15.3.4 PRODUCT PORTFOLIO 149
    • 15.3.5 RECENT DEVELOPMENT 149
      • 15.3.5.1 ACQUISITION 149
  • 15.4 IQVIA 150
    • 15.4.1 COMPANY SNAPSHOT 150
    • 15.4.2 REVENUE ANALYSIS 150
    • 15.4.3 COMPANY SHARE ANALYSIS 151
    • 15.4.4 PRODUCT PORTFOLIO 151
    • 15.4.5 RECENT DEVELOPMENTS 151
      • 15.4.5.1 ACQUISITION 151
  • 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 152
    • 15.5.1 COMPANY SNAPSHOT 152
    • 15.5.2 REVENUE ANALYSIS 152
    • 15.5.3 COMPANY SHARE ANALYSIS 153
    • 15.5.4 PRODUCT PORTFOLIO 153
    • 15.5.5 RECENT DEVELOPMENTS 153
      • 15.5.5.1 NEW LABORATORY 153
      • 15.5.5.2 ACQUISITION 153
  • 15.6 BANOOK 154
    • 15.6.1 COMPANY SNAPSHOT 154
    • 15.6.2 PRODUCT PORTFOLIO 154
    • 15.6.3 RECENT DEVELOPMENT 154
      • 15.6.3.1 AGREEMENT 154
  • 15.7 BIOTRIAL 155
    • 15.7.1 COMPANY SNAPSHOT 155
    • 15.7.2 PRODUCT PORTFOLIO 155
    • 15.7.3 RECENT DEVELOPMENT 155
      • 15.7.3.1 NEW CENTER OPENING 155
  • 15.8 CELERION 156
    • 15.8.1 COMPANY SNAPSHOT 156
    • 15.8.2 PRODUCT PORTFOLIO 156
    • 15.8.3 RECENT DEVELOPMENT 156
      • 15.8.3.1 NEW CENTER OPENING 156
  • 15.9 CERTARA 157
    • 15.9.1 COMPANY SNAPSHOT 157
    • 15.9.2 REVENUE ANALYSIS 157
    • 15.9.3 PRODUCT PORTFOLIO 158
    • 15.9.4 RECENT DEVELOPMENTS 158
      • 15.9.4.1 CONTRACT 158
      • 15.9.4.2 ACQUISITION 158
  • 15.10 CLARIO 159
    • 15.10.1 COMPANY SNAPSHOT 159
    • 15.10.2 PRODUCT PORTFOLIO 159
    • 15.10.3 RECENT DEVELOPMENT 159
      • 15.10.3.1 PRODUCT EXPANSION 159
  • 15.11 MEDPACE 160
    • 15.11.1 COMPANY SNAPSHOT 160
    • 15.11.2 REVENUE ANALYSIS 160
    • 15.11.3 PRODUCT PORTFOLIO 161
    • 15.11.4 RECENT DEVELOPMENTS 161
      • 15.11.4.1 ACQUISITION 161
  • 15.12 NCARDIA 162
    • 15.12.1 COMPANY SNAPSHOT 162
    • 15.12.2 PRODUCT PORTFOLIO 162
    • 15.12.3 RECENT DEVELOPMENT 162
      • 15.12.3.1 PARTNERSHIP 162
  • 15.13 NEXEL CO., LTD 163
    • 15.13.1 COMPANY SNAPSHOT 163
    • 15.13.2 PRODUCT PORTFOLIO 163
    • 15.13.3 RECENT DEVELOPMENTS 163
      • 15.13.3.1 JOINT VENTURE 163
      • 15.13.3.2 PARTNERSHIP 164
  • 15.14 PHYSIOSTIM 165
    • 15.14.1 COMPANY SNAPSHOT 165
    • 15.14.2 PRODUCT PORTFOLIO 165
    • 15.14.3 RECENT DEVELOPMENT 165
      • 15.14.3.1 PARTNERSHIP 165
  • 15.15 RICHMOND PHARMACOLOGY 166
    • 15.15.1 COMPANY SNAPSHOT 166
    • 15.15.2 PRODUCT PORTFOLIO 166
    • 15.15.3 RECENT DEVELOPMENT 166
      • 15.15.3.1 EVENT 166
  • 15.16 SGS SA 167
    • 15.16.1 COMPANY SNAPSHOT 167
    • 15.16.2 REVENUE ANALYSIS 167
    • 15.16.3 PRODUCT PORTFOLIO 168
    • 15.16.4 RECENT DEVELOPMENT 168
      • 15.16.4.1 ACQUISITION 168
  • 15.17 SHANGHAI MEDICILON INC. 169
    • 15.17.1 COMPANY SNAPSHOT 169
    • 15.17.2 PRODUCT PORTFOLIO 169
    • 15.17.3 RECENT DEVELOPMENTS 169
      • 15.17.3.1 PARTNERSHIP 169
      • 15.17.3.2 PARTNERSHIP 170

16 QUESTIONNAIRE 171

17 RELATED REPORTS 173

LIST OF TABLES

  • TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 41
  • TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA 42
  • TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE) 42
  • TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION 43
  • TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 45
  • TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS 47
  • TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES 49
  • TABLE 8 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 65
  • TABLE 9 EUROPE ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 66
  • TABLE 10 EUROPE BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 11 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 12 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 68
  • TABLE 13 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 68
  • TABLE 14 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 69
  • TABLE 15 EUROPE CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 16 EUROPE REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 17 EUROPE CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 71
  • TABLE 18 EUROPE NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
  • TABLE 19 EUROPE PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
  • TABLE 20 EUROPE THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 21 EUROPE TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 22 EUROPE PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 23 EUROPE OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 24 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 79
  • TABLE 25 EUROPE PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 80
  • TABLE 26 EUROPE PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 27 EUROPE PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 28 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 29 EUROPE INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 86
  • TABLE 30 EUROPE STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 31 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 91
  • TABLE 32 EUROPE PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 34 EUROPE ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 35 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 100
  • TABLE 36 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 100
  • TABLE 37 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
  • TABLE 38 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
  • TABLE 39 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
  • TABLE 40 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 101
  • TABLE 41 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 102
  • TABLE 42 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 102
  • TABLE 43 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
  • TABLE 44 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
  • TABLE 45 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
  • TABLE 46 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
  • TABLE 47 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 104
  • TABLE 48 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
  • TABLE 49 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 105
  • TABLE 50 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
  • TABLE 51 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
  • TABLE 52 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
  • TABLE 53 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
  • TABLE 54 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 107
  • TABLE 55 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 107
  • TABLE 56 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 108
  • TABLE 57 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 109
  • TABLE 58 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 109
  • TABLE 59 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
  • TABLE 60 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
  • TABLE 61 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 110
  • TABLE 62 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
  • TABLE 63 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 111
  • TABLE 64 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 112
  • TABLE 65 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 112
  • TABLE 66 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
  • TABLE 67 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
  • TABLE 68 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 113
  • TABLE 69 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 113
  • TABLE 70 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 114
  • TABLE 71 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 115
  • TABLE 72 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 115
  • TABLE 73 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 116
  • TABLE 74 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 116
  • TABLE 75 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 116
  • TABLE 76 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 77 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 117
  • TABLE 78 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 118
  • TABLE 79 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 118
  • TABLE 80 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 119
  • TABLE 81 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 119
  • TABLE 82 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 119
  • TABLE 83 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 119
  • TABLE 84 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 120
  • TABLE 85 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 121
  • TABLE 86 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 121
  • TABLE 87 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 122
  • TABLE 88 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 122
  • TABLE 89 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 122
  • TABLE 90 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
  • TABLE 91 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 123
  • TABLE 92 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 124
  • TABLE 93 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 124
  • TABLE 94 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 125
  • TABLE 95 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 125
  • TABLE 96 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 125
  • TABLE 97 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 98 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 126
  • TABLE 99 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 127
  • TABLE 100 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 127
  • TABLE 101 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 128
  • TABLE 102 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 128
  • TABLE 103 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 128
  • TABLE 104 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 105 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 129
  • TABLE 106 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 130
  • TABLE 107 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 130
  • TABLE 108 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 131
  • TABLE 109 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 131
  • TABLE 110 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 131
  • TABLE 111 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 112 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 132
  • TABLE 113 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 133

LIST OF FIGURES

  • FIGURE 1 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 21
  • FIGURE 2 EUROPE CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION 24
  • FIGURE 3 EUROPE CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS 25
  • FIGURE 4 EUROPE CARDIAC SAFETY SERVICES MARKET: EUROPE VS COUNTRY MARKET ANALYSIS 26
  • FIGURE 5 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS 26
  • FIGURE 6 EUROPE CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS 28
  • FIGURE 7 EUROPE CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID 29
  • FIGURE 8 EUROPE CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID 31
  • FIGURE 9 EUROPE CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS 32
  • FIGURE 10 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 36
  • FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE EUROPE CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 37
  • FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029 37
  • FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG 45
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE CARDIAC SAFETY SERVICES MARKET 53
  • FIGURE 15 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021 61
  • FIGURE 16 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION) 62
  • FIGURE 17 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029) 63
  • FIGURE 18 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE 64
  • FIGURE 19 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021 76
  • FIGURE 20 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION) 77
  • FIGURE 21 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029) 77
  • FIGURE 22 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE 78
  • FIGURE 23 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021 82
  • FIGURE 24 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION) 83
  • FIGURE 25 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029) 83
  • FIGURE 26 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE 84
  • FIGURE 27 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021 88
  • FIGURE 28 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION) 89
  • FIGURE 29 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029) 89
  • FIGURE 30 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE 90
  • FIGURE 31 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021) 95
  • FIGURE 32 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021) 96
  • FIGURE 33 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029) 96
  • FIGURE 34 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029) 97
  • FIGURE 35 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029) 98
  • FIGURE 36 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%) 133